Hot Investor Mandate: Investment Arm of Asia-Based Pharmaceutical Company Seeks Equity Investment and In-Licensing Opportunities in Novel Therapeutic Modalities

26 Jan

A pharmaceutical company headquartered in Asia has 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.). The firm’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading.

The firm’s investment subsidiary is responsible for equity investment and in-licensing activities for its corporate parent.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilars. The firm is interested in distribution rights in China. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: